These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 7755474

  • 1. [Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog].
    Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.
    Arch Mal Coeur Vaiss; 1994 Aug; 87(8):971-4. PubMed ID: 7755474
    [Abstract] [Full Text] [Related]

  • 2. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
    Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.
    J Pharmacol Exp Ther; 1994 Feb; 268(2):747-52. PubMed ID: 8113986
    [Abstract] [Full Text] [Related]

  • 3. Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741.
    Schumacher WA, Heran CL, Ogletree ML.
    Eicosanoids; 1990 Feb; 3(2):87-93. PubMed ID: 2144979
    [Abstract] [Full Text] [Related]

  • 4. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P, Ferrario CM, Brosnihan KB.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [Abstract] [Full Text] [Related]

  • 5. AT1 and TxA2/PGH2 receptors maintain hypertension throughout 2K,1C Goldblatt hypertension in the rat.
    Wilcox CS, Cardozo J, Welch WJ.
    Am J Physiol; 1996 Oct; 271(4 Pt 2):R891-6. PubMed ID: 8897978
    [Abstract] [Full Text] [Related]

  • 6. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
    Li P, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1065-70. PubMed ID: 9190837
    [Abstract] [Full Text] [Related]

  • 7. Effects of losartan on contractile responses of conductance and resistance arteries from rats.
    Corriu C, Bernard S, Schott C, Stoclet JC.
    J Cardiovasc Pharmacol; 1995 Nov; 26(5):688-92. PubMed ID: 8637181
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
    Cassis LA, Rippetoe PE, Soltis EE, Painter DJ, Fitz R, Gillespie MN.
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1168-72. PubMed ID: 1527721
    [Abstract] [Full Text] [Related]

  • 9. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide.
    Tesfamariam B.
    J Hypertens; 1994 Jan; 12(1):41-7. PubMed ID: 8157943
    [Abstract] [Full Text] [Related]

  • 10. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D.
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [Abstract] [Full Text] [Related]

  • 11. Discovery of losartan, the first angiotensin II receptor antagonist.
    Timmermans PB, Duncia JV, Carini DJ, Chiu AT, Wong PC, Wexler RR, Smith RD.
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
    [Abstract] [Full Text] [Related]

  • 12. [Contribution of the renin-angiotensin system to the variability of blood pressure in hypertensive rat after blockade of nitric oxide synthesis].
    Gouédard O, Gaudet E, Blanc J, Ponchon P, Elghozi JL.
    Arch Mal Coeur Vaiss; 1996 Aug; 89(8):1013-7. PubMed ID: 8949370
    [Abstract] [Full Text] [Related]

  • 13. Prostaglandin B2-induced pulmonary hypertension is mediated by TxA2/PGH2 receptor stimulation.
    Liu F, Orr JA, Wu JY.
    Am J Physiol; 1994 Nov; 267(5 Pt 1):L602-8. PubMed ID: 7977770
    [Abstract] [Full Text] [Related]

  • 14. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
    Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB.
    J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
    [Abstract] [Full Text] [Related]

  • 15. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B.
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [Abstract] [Full Text] [Related]

  • 16. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects.
    Gorbea-Oppliger VJ, Melaragno MG, Potter GS, Petit RL, Fink GD.
    J Pharmacol Exp Ther; 1994 Nov; 271(2):804-10. PubMed ID: 7965799
    [Abstract] [Full Text] [Related]

  • 17. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
    Bertolino F, Valentin JP, Maffre M, Grelac F, Bessac AM, Maclouf J, Delhon A, Lévy-Toledano S, Patoiseau JF, Colpaert FC.
    Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
    [Abstract] [Full Text] [Related]

  • 18. Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats.
    Gao H, Welch WJ, DiBona GF, Wilcox CS.
    Am J Physiol; 1997 Aug; 273(2 Pt 2):H734-9. PubMed ID: 9277490
    [Abstract] [Full Text] [Related]

  • 19. Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade?
    Brunner HR.
    J Hum Hypertens; 1995 Nov; 9(11):859-60. PubMed ID: 8583462
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Nov; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.